S63845
目录号 : GC12621
S63845是一种有效的选择性骨髓细胞白血病1（MCL1）抑制剂，Kd值为0.19nM（人MCL1）。
Cas No.:1799633-27-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
S63845 is an effective and selective inhibitor of bone marrow cell leukemia 1 (MCL1), with a Kd value of 0.19nM (for human MCL1) [1]. MCL1 is a pro-survival protein belonging to the BCL-2 family and is overexpressed in many cancers [2]. S63845 can be used for therapeutic research on multiple myeloma, leukemia, and lymphoma cell lines [3].
In vitro, S63845 (0.25, 0.5, and 1.0μM; 24 and 48h) significantly induces apoptosis in two cell lines (HH and HuT-78) in a dose-dependent manner, with decreased cell viability, loss of mitochondrial membrane potential, and activation of caspases [4]. S63845 (0-1280nM; 32 and 48h) in combination with the tyrosine kinase inhibitor imatinib reduces the viability of two cells (K562 and JURL-MK1), and significantly reduces the expression of MCL1, cIAP1, and survivin in K562 cells, while there is a slight upregulation in TCCS cells [5].
In vivo, S63845 (25 and 50mg/kg/day for 5 days; intravenous) can inhibit the generation of red blood cells (RBC) and lymph (LYMPH) in the blood of mice with hematopoietic injury models in the early stage, and restore it in the late stage. During the entire observation period, the platelet (PLT) count in the blood increases [6]. S63845 (25mg/kg/day; twice per week for 3 weeks; intravenous) in combination with regorafenib significantly improves the survival rate of mice in the 143B-luc lung metastasis model [7].
References:
[1] Kotschy A, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016 Oct 27;538(7626):477-482.
[2] Li Z, He S, Look A T. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells[J]. Leukemia, 2019, 33(1): 262-266.
[3] Algarín E M, Díaz-Tejedor A, Mogollón P, et al. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma[J]. Haematologica, 2020, 105(3): e116.
[4] Sumarni U, Zhu J, Sinnberg T, et al. Sensitivity of cutaneous T-cell lymphoma cells to the Mcl-1 inhibitor S63845 correlates with the lack of Bcl-w expression[J]. International Journal of Molecular Sciences, 2022, 23(20): 12471.
[5] Malyukova A, Ujvari D, Yektaei-Karin E, et al. Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells[J]. Cell Death & Disease, 2021, 12(10): 875.
[6] Zhang H, Li F, Yang M, et al. MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis[J]. Pharmaceutics, 2023, 15(4): 1085.
[7] Ji Y, Harris M A, Newton L M, et al. Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo[J]. BMC cancer, 2024, 24(1): 1350.
S63845是一种有效的选择性骨髓细胞白血病1（MCL1）抑制剂，Kd值为0.19nM（人MCL1） [1]。MCL1是一种属于BCL-2家族蛋白的促存活蛋白，在许多癌症中过度表达 [2]。S63845可用于多发性骨髓瘤、白血病和淋巴瘤细胞系的治疗研究 [3]。
在体外，S63845（0.25, 0.5 and 1.0μM; 24, 48h）以剂量依赖的方式显著诱导两种细胞系（HH、HuT-78）发生凋亡，细胞活力下降，线粒体膜电位丧失和半胱天冬酶激活 [4]。S63845（0-1280nM; 32, 48h）与酪氨酸激酶抑制剂imatinib的联合治疗降低了两种细胞（K562和JURL-MK1）的活力，并且显著降低了K562细胞中MCL1、cIAP1和survivin的表达，而在TCCS细胞中则有轻微上调作用 [5]。
在体内，S63845（25 and 50mg/kg/day for 5 days; i.v.）在早期能够抑制造血损伤模型小鼠血液中红细胞（RBC）和淋巴（LYMPH）的生成，而在晚期恢复。在整个观察期间血液中血小板（PLT）计数增加 [6]。S63845（25mg/kg/day; twice per week for 3 weeks; i.v.）与regorafenib联合治疗显著提高了143B-luc肺转移瘤模型小鼠的生存率 [7]。
| Cell experiment [1]: | |
Cell lines | HH and HuT-78 cells |
Preparation Method | Cells were maintained at 37 °C and 5% CO2 in RPMI 1640 growth medium supplemented with fetal calf serum (FCS, 10%), L-glutamine (600μM) and antibiotics. 5 × 104 cells were seeded per well in 24-well plates. Cells were treated with 0.25, 0.5, 1.0µM S63845. After 24 and 48h, apoptotic rates were determined by sub-G1 assay, and rates of cell viability were determined by calcein staining. |
Reaction Conditions | 0.25, 0.5, 1.0μM; 24, 48h |
Applications | S63845 significantly induced apoptosis and reduced cell viability in both types of cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | CB6F1 mice (Hematopoietic Suppression Model) |
Preparation Method | All female mice (6–8 weeks old) were randomly and evenly classified, by weight, into different experimental groups after one week of adaptive rearing under SPF conditions. Mice were classified into three groups: the control group was treated with a vehicle, and the 25mg/kg and 50mg/kg groups were injected with the S63845 solution. S63845 was dissolved in 25mM HCl and 20% 2-hydroxy propyl β-cyclodextrin, which were used as soon as they were ready. The mice were treated with a dose of vehicle or S63845 (the 25mg/kg and 50mg/kg groups) via tail vein injection. This was administered once a day for 5 consecutive days from day 0 (the first day of administration) to day 4. The mice were sacrificed on day 7 or day 22. Peripheral blood (PB) was collected from the tail veins of living mice and analyzed using an automated hematology analyzer. |
Dosage form | 25 and 50mg/kg/day for 5 days; i.v. |
Applications | S63845 initially inhibited the production of red blood cells (RBC) and lymphocytes (LYMPH) in the blood of mice, but restored it in the later stage. During the entire observation period, an increase in platelet (PLT) count was observed. |
References: | |
| Cas No. | 1799633-27-4 | SDF | |
| 化学名 | (S)-2-(((S)-5-(3-chloro-2-methyl-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-6-(5-fluorofuran-2-yl)thieno[2,3-d]pyrimidin-4-yl)oxy)-3-(2-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)methoxy)phenyl)propanoic acid | ||
| Canonical SMILES | OC([C@@H](OC1=NC=NC2=C1[C@]([C@]3=C(C)C(Cl)=C(C=C3)OCCN4CCN(C)CC4)=C(C5=CC=C(F)O5)S2)CC6=CC=CC=C6OCC7=CC=NN7CC(F)(F)F)=O | ||
| 分子式 | C39H37ClF4N6O6S | 分子量 | 829.26 |
| 溶解度 | ≥ 41.45mg/mL in DMSO, ≥ 20mg/mL in MeOH | 储存条件 | 4°C, protect from light, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2059 mL | 6.0295 mL | 12.0589 mL |
| 5 mM | 241.2 μL | 1.2059 mL | 2.4118 mL |
| 10 mM | 120.6 μL | 602.9 μL | 1.2059 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet